Prognostic role of CD82/KAI1 in multiple human malignant neoplasms: a meta-analysis of 31 studies
Jundong Zhu,* Chenkui Miao,* Shouyong Liu,* Ye Tian, Chao Zhang, Chao Liang, Aiming Xu, Qiang Cao, Zengjun Wang Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China *These authors contributed equally to this work Abstract: Tetraspanin CD82, also known as KAI1, was revealed as an attractive prognostic tumor biomarker in recent studies. However, some results of these studies remained debatable and inconclusive. Therefore, we conducted a meta-analysis to clarify the precise predictive value of CD82 in various neoplasms. Qualified studies were identified up to April 27, 2017, by searching PubMed, EMBASE, and the Web of Science. In total, 29 eligible studies were ultimately enrolled in this meta-analysis. Pooled hazard ratios (HRs) with 95% CIs of overall survival and disease/recurrence/progression-free survival were calculated to evaluate the correct prognostic role of CD82. Statistical analysis demonstrated that high expression of CD82 was significantly associated with enhanced overall survival (HR =0.56, 95% CI: 0.47–0.67) and disease/recurrence/progression-free survival (HR =0.42, 95% CI: 0.30–0.59) in cancer patients. Furthermore, we also conducted the subgroup analysis and the results revealed that CD82 was associated with favorable outcomes in cancer patients. Taken together, CD82 could be a promising biomarker for predicting the prognosis of patients with malignant neoplasms, and the biological functions of CD82 are of great research value of the subject. Keywords: CD82, KAI1, prognosis, meta-analysis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
OncoTargets and Therapy - (2017), Seite 5805-5816 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu J [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
CD82/KAI1 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ045999422 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ045999422 | ||
| 003 | DE-627 | ||
| 005 | 20230501200554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2017 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ045999422 | ||
| 035 | |a (DE-599)DOAJ84d794d26dcd4255bb1b0e82fd357f87 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Zhu J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic role of CD82/KAI1 in multiple human malignant neoplasms: a meta-analysis of 31 studies |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Jundong Zhu,* Chenkui Miao,* Shouyong Liu,* Ye Tian, Chao Zhang, Chao Liang, Aiming Xu, Qiang Cao, Zengjun Wang Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China *These authors contributed equally to this work Abstract: Tetraspanin CD82, also known as KAI1, was revealed as an attractive prognostic tumor biomarker in recent studies. However, some results of these studies remained debatable and inconclusive. Therefore, we conducted a meta-analysis to clarify the precise predictive value of CD82 in various neoplasms. Qualified studies were identified up to April 27, 2017, by searching PubMed, EMBASE, and the Web of Science. In total, 29 eligible studies were ultimately enrolled in this meta-analysis. Pooled hazard ratios (HRs) with 95% CIs of overall survival and disease/recurrence/progression-free survival were calculated to evaluate the correct prognostic role of CD82. Statistical analysis demonstrated that high expression of CD82 was significantly associated with enhanced overall survival (HR =0.56, 95% CI: 0.47–0.67) and disease/recurrence/progression-free survival (HR =0.42, 95% CI: 0.30–0.59) in cancer patients. Furthermore, we also conducted the subgroup analysis and the results revealed that CD82 was associated with favorable outcomes in cancer patients. Taken together, CD82 could be a promising biomarker for predicting the prognosis of patients with malignant neoplasms, and the biological functions of CD82 are of great research value of the subject. Keywords: CD82, KAI1, prognosis, meta-analysis | ||
| 650 | 4 | |a CD82/KAI1 | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a meta-analysis | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Miao C |e verfasserin |4 aut | |
| 700 | 0 | |a Liu S |e verfasserin |4 aut | |
| 700 | 0 | |a Tian Y |e verfasserin |4 aut | |
| 700 | 0 | |a Zhang C |e verfasserin |4 aut | |
| 700 | 0 | |a Liang C |e verfasserin |4 aut | |
| 700 | 0 | |a Xu A |e verfasserin |4 aut | |
| 700 | 0 | |a Cao Q |e verfasserin |4 aut | |
| 700 | 0 | |a Wang Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t OncoTargets and Therapy |d Dove Medical Press, 2009 |g (2017), Seite 5805-5816 |w (DE-627)DOAJ000108448 |x 11786930 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g pages:5805-5816 |
| 856 | 4 | 0 | |u https://doaj.org/article/84d794d26dcd4255bb1b0e82fd357f87 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.dovepress.com/prognostic-role-of-cd82kai1-in-multiple-human-malignant-neoplasms-a-me-peer-reviewed-article-OTT |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1178-6930 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2017 |h 5805-5816 | ||